



**DECLARATION  
Utility Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "**TAT-Derived Oligourea and Its Method of Production and Use in High-Affinity and Specific Binding of HIV-1 Tar RNA**" the specification of which

(Check One) ☐ is attached hereto OR  
☒ was filed on July 25, 2001 as United States Application Serial No. 09/889,982 and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date
60/117,099	January 25, 1999

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned
	PCT/US00/01957	January 25, 2000	



**DECLARATION  
Utility Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **"TAT-Derived Oligopurea and Its Method of Production and Use in High-Affinity and Specific Binding of HIV-1 Tar RNA"** the specification of which

(Check One) ☐ is attached hereto OR  
☒ was filed on July 25, 2001 as United States Application Serial No. 09/889,982 and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date
60/117,099	January 25, 1999

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned
	PCT/US00/01957	January 25, 2000	



**DECLARATION  
Utility Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "**TAT-Derived Oligourea and Its Method of Production and Use in High-Affinity and Specific Binding of HIV-1 Tar RNA**" the specification of which

(Check One) ☐ is attached hereto OR  
☒ was filed on July 25, 2001 as United States Application Serial No. 09/889,982 and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date
60/117,099	January 25, 1999

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned
	PCT/US00/01957	January 25, 2000	

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

201	FULL NAME OF INVENTOR	FIRST Name <u>Tariq</u>	MIDDLE Initial <u>M.</u>	LAST Name <u>RANA</u>	
	RESIDENCE & CITIZENSHIP	City <u>Shrewsbury</u>	State or Foreign Country <u>Massachusetts</u> <u>MA</u>		Country of Citizenship <u>USA</u>
	POST OFFICE ADDRESS	<u>40 Keyes House Rd.</u>	City <u>Shrewsbury</u>	State or Country <u>Massachusetts</u>	Zip Code <u>01545</u>
INVENTOR'S SIGNATURE <u>Tariq Rana</u> DATE <u>11/01/01</u>					

202	FULL NAME OF INVENTOR	FIRST Name <u>N.</u>	MIDDLE Initial	LAST Name <u>Tamilarasu</u>	
	RESIDENCE & CITIZENSHIP	City <u>Highland Park</u>	State or Foreign Country <u>New Jersey</u>		Country of Citizenship <u>India</u>
	POST OFFICE ADDRESS	<u>30-C Bartle Court</u>	City <u>Highland Park</u>	State or Country <u>NJ</u>	Zip Code <u>08904</u>
INVENTOR'S SIGNATURE _____ DATE _____					

203	FULL NAME OF INVENTOR	FIRST Name <u>Ikramul</u>	MIDDLE Initial	LAST Name <u>Huq</u>	
	RESIDENCE & CITIZENSHIP	City <u>Edison</u>	State or Foreign Country <u>New Jersey</u>		Country of Citizenship <u>Bangladesh</u>
	POST OFFICE ADDRESS	<u>42 Florence Street</u>	City <u>Edison</u>	State or Country <u>NJ</u>	Zip Code <u>08817</u>
INVENTOR'S SIGNATURE _____ DATE _____					

204	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country		Country of Citizenship
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE _____ DATE _____					

205	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country		Country of Citizenship
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE _____ DATE _____					

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

201	FULL NAME OF INVENTOR	FIRST Name Tariq	MIDDLE Initial M.	LAST Name RANA	
	RESIDENCE & CITIZENSHIP	City Shrewsbury	State or Foreign Country Massachusetts		Country of Citizenship USA
	POST OFFICE ADDRESS	40 Keyes House Rd.	City Shrewsbury	State or Country Massachusetts	Zip Code 01545
INVENTOR'S SIGNATURE _____ DATE _____					

202	FULL NAME OF INVENTOR	FIRST Name <u>N.</u>	MIDDLE Initial	LAST Name <u>Tamilarasu</u>	
	RESIDENCE & CITIZENSHIP	City <u>Highland Park</u>	State or Foreign Country New Jersey <u>NJ</u>		Country of Citizenship India
	POST OFFICE ADDRESS	30-C Bartle Court	City Highland Park	State or Country NJ	Zip Code 08904
INVENTOR'S SIGNATURE <u>Tamir</u> DATE <u>10/30/01</u>					

203	FULL NAME OF INVENTOR	FIRST Name Ikramul	MIDDLE Initial	LAST Name Huq	
	RESIDENCE & CITIZENSHIP	City Edison	State or Foreign Country New Jersey		Country of Citizenship Bangladesh
	POST OFFICE ADDRESS	42 Florence Street	City Edison	State or Country NJ	Zip Code 08817
INVENTOR'S SIGNATURE _____ DATE _____					

204	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country		Country of Citizenship
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE _____ DATE _____					

205	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country		Country of Citizenship
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE _____ DATE _____					

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

201	FULL NAME OF INVENTOR	FIRST Name Tariq	MIDDLE Initial M.	LAST Name RANA	
	RESIDENCE & CITIZENSHIP	City Shrewsbury	State or Foreign Country Massachusetts		Country of Citizenship USA
	POST OFFICE ADDRESS	40 Keyes House Rd.	City Shrewsbury	State or Country Massachusetts	Zip Code 01545
INVENTOR'S SIGNATURE _____ DATE _____					

202	FULL NAME OF INVENTOR	FIRST Name N.	MIDDLE Initial	LAST Name Tamilarasu	
	RESIDENCE & CITIZENSHIP	City Highland Park	State or Foreign Country New Jersey		Country of Citizenship India
	POST OFFICE ADDRESS	30-C Bartle Court	City Highland Park	State or Country NJ	Zip Code 08904
INVENTOR'S SIGNATURE _____ DATE _____					

203	FULL NAME OF INVENTOR	FIRST Name <u>Ikramul</u>	MIDDLE Initial	LAST Name <u>Huq</u>	
	RESIDENCE & CITIZENSHIP	City <u>Edison</u>	State or Foreign Country New Jersey <u>NJ</u>		Country of Citizenship Bangladesh
	POST OFFICE ADDRESS	42 Florence Street	City Edison	State or Country NJ	Zip Code 08817
INVENTOR'S SIGNATURE <u>[Signature]</u> DATE <u>10-29-01</u>					

204	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country		Country of Citizenship
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE _____ DATE _____					

205	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country		Country of Citizenship
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE _____ DATE _____					

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

13257-00018

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

097 889982

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/US00/01957

25 January 2000 (25.01.00)

25 January 1999 (25.01.99)

TITLE OF INVENTION Biopolymers Comprisihg Human Immunodeficiency Virus Tat

APPLICANT(S) FOR DO/EO/US RANA, Tariq M.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

09/889982

PCT/US00/01957

21. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO ..... \$1000.00

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =****CALCULATIONS PTO USE ONLY**

\$ 100.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	26 -20 =	6	x \$18.00	\$ 108.00
Independent claims	4 -3 =	1	x \$80.00	\$ 80.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 0.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 0.00
<b>SUBTOTAL =</b>				\$
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$
<b>TOTAL NATIONAL FEE =</b>				\$
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 188.00
<b>TOTAL FEES ENCLOSED =</b>				\$
				Amount to be refunded: \$
				charged: \$

\$

\$ 108.00

\$ 80.00

\$ 0.00

\$

\$

\$ 0.00

\$

\$

\$

\$

\$ 188.00

\$

\$

\$

a. ☒ A check in the amount of \$ 188.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1089. A duplicate copy of this sheet is enclosed.d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Janet E. Reed  
Saul Ewing  
1500 Market Street, 38th Floor  
Centre Square Building West  
Philadelphia, PA 19102

SIGNATURE

Janet E. Reed

NAME

36,252

REGISTRATION NUMBER



**Tat-derived Oligourea and Its Method of Production  
and Use in High Affinity and Specific Binding  
of HIV-1 TAR RNA**

This work was supported in part by the National Institutes of Health Grants Al 34785 and Al 01369, TW 00702. Tariq M. Rana is a recipient of Research Career Development Award from NIH.

5

**Field of the Invention**

This invention relates to a synthesized oligourea containing the basic-arginine rich region of Tat, the method of production of this oligourea and the use thereof. In particular, this invention relates to the design of drugs comprising the oligourea backbone of the invention, further comprising amino acid side chains. Similarly, the DNA-binding oligourea of the invention can also be synthesized to control biological processes involving DNA-protein interactions

15

**Background of the Invention**

Various scientific and scholarly articles are referred to in brackets and footnotes throughout the specification. These articles are incorporated by reference herein to describe the state of the art to which this invention pertains. Full citations of the references appear at the end of the specification.

20

Protein-nucleic acid interactions are involved in many cellular functions such as transcription, RNA splicing, and translation. Small peptides with unnatural backbones that can bind with high affinity to a specific sequence or structure of nucleic acids and interfere with protein-nucleic acid interactions would provide useful tools in molecular biology and medicine. Recently, minor-groove-binding polyamide ligands have been designed for sequence-specific recognition of DNA.<sup>1</sup> In contrast to DNA, RNA molecules can fold into extensive structures

25

30

-2-

containing regions of double-stranded duplex, hairpins, internal loops, bulged bases and pseudo-knotted structures.<sup>2</sup> The complexity of RNA structure makes it difficult to design ligands for sequence-specific RNA-recognition. Three-dimensional structures of RNA create binding sites for specific interactions with proteins.

One example of such interactions is the mechanism of trans-activation of human immunodeficiency virus type 1 (HIV-1) gene expression that requires the interaction of Tat protein with the trans-activation responsive region (TAR) RNA, a 59-base stem-loop structure located at the 5'-end of all nascent HIV-1 transcripts.<sup>3</sup> Replication of human immunodeficiency virus type 1 (HIV-1) requires specific interactions of Tat protein with the TAR RNA. Inhibition of Tat-TAR interactions is a potential approach for anti-HIV therapeutics. Since structural information is now available for TAR RNA and TAR-Tat peptide complexes from NMR<sup>4</sup>, photocrosslinking,<sup>5</sup> and affinity cleaving studies,<sup>6</sup> it is possible to design small molecules to interfere with Tat-TAR function. We have recently begun to examine TAR RNA recognition by unnatural biopolymers.<sup>7</sup>

#### Objects of the Invention

It is an object of the invention to provide substances which have higher binding affinities for RNA than natural peptides, which are resistant to proteases and which can interact with nucleic acids in a fashion similar to natural peptides. Such substances can be used to inhibit protein-nucleic acid interactions important for cellular processes.

It is a further object of the invention to provide a substance inhibiting protein-nucleic acid interactions. In particular, it is an object of the invention to provide a substance which controls

-3-

biological processes involving DNA-protein interactions, and which inhibit transcription in HIV-1 infected cells. Such a substance leads to the design of drugs based on the substance.

5           The current invention comprises a novel synthesized oligourea containing the basic-arginine rich region of Tat. The oligourea of the invention shows specific recognition of HIV-1 TAR RNA.

10           Other objects and advantages of the invention will become apparent to those skilled in the art from the accompanying description of the invention.

#### Brief Description of the Drawings

15           **Figure 1A:** The Tat-derived peptide, amino acids 48 to 57, contains the RNA-binding domain of Tat protein (SEQ ID NO:1). **Figure 1B:** Structure of the generic oligourea backbone. Side-chains corresponding to a desired amino acid are substituted at the R<sub>1</sub> and R<sub>2</sub> positions. Sequence of Tat-derived oligourea corresponds to the side-chains of the Tat peptide shown in (A), except the addition of an L-Tyr amino acid at the carboxyl-terminus. Tat-derived oligourea was synthesized on solid support by using activated *p*-nitrophenyl carbamates and azides of protected amines followed by  
20           reduction with SnCl<sub>2</sub>-thiophenol-triethylamine (Kim, J. M.; Bi, Y. Z.; Paikoff, S. J.; Schultz, P. G. *Tetrahedron Lett.* 1996, 37, 5305- 5308; Kick, B.; Bllman, J. *J Med. Chem.* 1995, 38, 1427-1430; incorporated by reference herein). After cleavage from the resin, the oligourea  
25           was purified by HPLC on a Zorbax 300 SB-C<sub>8</sub> column (Wang, Z.; Rana, T. M. *J Am. Chem. Soc.* 1995, 117, 5438-5444; Wang, Z.; Rana, T. M. *Biochemistry* 1996, 35, 6491-6499; Wang, Z.; Wang, x.; Rana, T. M. *J Biol. Chem.* 1996, 27, 16995-16998; incorporated by reference herein). The mass  
30

-4-

of fully deprotected and purified oligourea was confirmed by ES and MALDI mass spectrometry; 1849.2 (M +H).

**Figure 2A:** Secondary structure of wild-type TAR RNA used in this study. Wild-type TAR RNA spans the minimal sequences that are required for Tat responsiveness *in vivo*<sup>14</sup> and for *in vitro* binding of Tat-derived peptides.<sup>9</sup> Wild-type TAR contains two non-wild-type base pairs to increase transcription by T7 RNA polymerase. Mutant M0 TAR contained no bulge residue in its sequence. In mutant G26C, a base-pair in the upper stem of TAR RNA, G26-C39 was substituted by C26-G39.

**Figure 2B:** Electrophoretic mobility shift analysis for the Tat-derived oligourea binding to wild-type and trinucleotide bulge mutant (M0) TAR RNA. 5'-end labeled TAR RNAs (40 nM) were heated to 85 °C for three minutes and then cooled to room temperature in TK buffer (50 mM Tris-HCl pH 7.4), 20 mM KCl, 0.1% Triton X-100). The oligourea (150 nM) was added to wild-type or mutant TAR and incubated at room temperature for one hour. After adding 30% glycerol, the oligourea-RNA complexes were resolved on a non-denaturing 12% acrylamide gel and visualized by autoradiography or phosphorimaging. **Figure 2C:** Specificity of the oligourea-TAR complex formation determined by competition experiments. Oligourea-RNA complexes were formed in the presence of increasing concentrations of unlabeled wild-type or mutant TAR RNAs. Concentrations of the competitor RNAs in lanes 3, 4, 5, 6 were 50, 100, 150, and 200 nM, respectively. Lanes 1 and 2 were marker lanes showing RNA and oligourea-RNA complexes. Oligourea-RNA complexes are labeled as R-P.

**Figure 3.** Site-specific photocrosslinking reaction of TAR RNA labeled with 4-thioUracil at position 23 with the oligourea. For photochemical reactions, RNA

-5-

duplex was prepared by hybridizing two strands.<sup>5,7</sup> Strand 1 of the duplex was 5'-end labeled with 32p Preformed RNA duplexes (40 nM) in the absence or presence of the oligourea (100 nM) were irradiated (360 um) and analyzed by denaturing gels as described earlier.<sup>5,7</sup> Proteinase K digestion was performed at 55 °C for fifteen minutes after LW irradiation. R-R and R-P XL indicate the RNA-RNA and RNA-oligourea crosslink, respectively.

**Figure 4.** Inhibition of Tat transactivation by the oligourea derivative *in vivo*. CAT activity expressed from the integrated HIV-1 LTR of HL3TI Cells with increasing amounts of oligourea is shown. Luciferase activity was a control experiment to monitor the transfection inhibition of pSV2Tat by the addition of oligourea. CAT and Luciferase activities were measured from multiple experiments and normalized to 100%. Control lane (labeled as positive) shows Tat transactivation in the absence of oligourea.

20

#### Detailed Description of the Invention

The invention provides a composition and method for inhibiting the interaction of a nucleic acid and specific binding protein *in vitro* and *in vivo*. The composition is an oligourea backbone as disclosed in figure 1B, with amino acid side-chains substituted at the R<sub>1</sub> and R<sub>2</sub> positions. In accordance with the invention, it has been discovered that the rigid and protease insensitive oligourea backbone, when substituted with a sequence of amino acid side-chains modeled after a known nucleic acid binding domain, will mimic the nucleic acid binding domain in specificity, but with a much lower disassociation constant. This nucleic acid binding composition may be used for research into the physiological effects of nucleic acid binding proteins,

-6-

assay methods for detecting nucleic acids and therapeutic methods for inhibiting protein-nucleic acid interactions that lead to disease states. Also provided, is a method for inhibiting protein-nucleic acid interactions *in vitro* and *in vivo* which entails introducing the oligourea molecules of the invention.

The composition of the invention is composed oligourea backbone, the generic form of which is disclosed in Fig. 1B, which supports the side chains of amino acids, at the  $R_1$  and  $R_2$  position of Fig. 2B. When the oligourea molecule has amino acid side chains that correspond to the side chains of a nucleic acid binding protein in composition and sequence, the oligourea molecule then binds to the target nucleic acid specifically and with a very low disassociation constant. In a preferred embodiment, the oligourea molecule has a dissociation constant upon binding the target nucleic acid of less than or equal to 0.7  $\mu\text{M}$  (less than or equal to 0.5  $\mu\text{M}$  more preferred; less than or equal to 0.3  $\mu\text{M}$  most preferred). In Example 1, the use of an oligourea molecule of the invention is illustrated which mimics the RNA-binding protein Tat. In a preferred embodiment, the oligourea molecule is comprised of amino acid side chains that mimic the Tat molecule. In a more preferred embodiment, the side-chains correspond to residues 48 - 57 of the Tat molecule, more preferred, SEQ ID NO:1. In a most preferred embodiment, the amino acid side-chains correspond to SEQ ID NO:1 with a L-Tyr amino acid at the carboxyl-terminus.

The composition of the invention encompasses a very diverse assortment of molecules, all with oligourea backbones and amino acid side-chains. The oligourea molecule may be any length which achieves the desired dissociation constant from the nucleic acid. In a preferred embodiment, the oligourea is 3 to 50 urea-units

-7-

long (5 to 30 more preferred, 8 to 25 most preferred). The oligoureia molecule may comprise amino acid side-chains that correspond to the binding region of any nucleic acid binding protein presently known or that will be discovered. Types of DNA binding proteins of interest include, but are not limited to, transcription control proteins (e.g. transcription factors, see Conaway and Conaway, 1994, Transcription Mechanisms and Regulation, Raven Press Series on Molecular and Cellular Biology, Vol. 3, Raven Press, Ltd., New York, NY), recombination enzymes (e.g. *hin* recombinase), DNA modifying enzymes (e.g. restriction enzymes), structural proteins (e.g. histones and nonhistone chromatin proteins such as HMG proteins), single-stranded DNA-binding proteins (e.g. those involved in the propagation of a DNA replication fork or in the packaging of T-DNA ssDNA) and double- and single-stranded RNA-binding proteins. RNA-binding proteins are also contemplated in regard to the present invention, (see, for example, Draper DE, J Mol Biol 1999 Oct 22;293(2):255-70; Haile DJ, Am J Med Sci 1999 Oct;318(4):230-40; Cusack S, Curr Opin Struct Biol 1999 Feb;9(1):66-73).

Transcription factors suitable for use with the present invention include, but are not limited to, homeobox proteins, zinc finger proteins, hormone receptors, helix-turn-helix proteins, helix-loop-helix proteins, basic-Zip proteins (bZip) and  $\beta$ -ribbon factors (see Harrison, 1991, Nature 353:715-719). Homeobox DNA-binding proteins contemplated for use with the instant invention include, but are not limited to, HOX, STF-1 (Leonard et al., 1993, Mol. Endo., 7:1275-1283; Scott et al. (1989), Biochem. Biophys. Acta, 989:25-48), Antp, Mat  $\alpha$ -2 and INV. Zinc finger DNA-binding proteins contemplated for use with the instant invention include, but are not limited to, Zif268, GLI and XFin. For

-8-

reviews of zinc-finger DNA-binding proteins see Klug and Rhodes (1987), Trends Biochem. Sci., 12:464; Jacobs and Michaels (1990), New Biol., 2:583; and Jacobs (1992), EMBO J., 11:4507-4517. Hormone receptor DNA-binding proteins contemplated for use with the instant invention include, but are not limited to, glucocorticoid receptor, thyroid hormone receptor and estrogen receptor (see, e.g., U.S. Pat. Nos. 4,981,784; 5,171,671; and 5,071,773). Helix-turn-helix DNA-binding proteins contemplated for use with the instant invention include, but are not limited to,  $\lambda$ -repressor, cro-repressor, 434 repressor and 434-cro (See, e.g., Pabo and Sauer, 1984, Annu. Rev. Biochem., 53:293-321). Helix-loop-helix DNA-binding proteins contemplated for use with the instant invention include, but are not limited to, MRF4 (Block et al., 1992, Mol. and Cell Biol., 12(6):2484-2492), CTF4 (Tsay et al., 1992, NAR, 20(10):2624), NSCL, PAL2 and USF (see, for review, Wright (1992), Current Opinion in Genetics and Development, 2(2):243-248; Kadesch, T. (1992), Immun. Today, 13(1):31-36; and Garell and Campuzano (1991), Bioessays, 13(10):493-498). Basic Zip DNA-binding proteins contemplated for use with the instant invention include, but are not limited to, GCN4, fos and jun (see, for review, Lamb and McKnight, 1991, Trends Biochem. Sci., 16:417-422).  $\beta$ -ribbon factors contemplated for use with the instant invention include, but are not limited to, Met-J, ARC, and MNT.

The oligonucleotide composition of the invention has a diverse range of uses. Any application that requires a strong nucleic acid binding molecule may use the oligonucleotide molecules of the invention. The oligonucleotide molecules may be used to inhibit the native nucleic acid binding molecule by competing with the native protein molecule for the binding site on the nucleic acid. This



-9-

application may be used for research purposes or for therapy purposes. In therapeutic methods, the oligourea molecules of the invention may be used to inhibit a protein-nucleic interaction that leads to a disease state. Example 1 illustrates the use of an oligourea molecule to inhibit the interaction between the Tat protein and the TAR RNA from HIV. Finally, the oligourea molecule may be used to detect the presence of the target nucleic acid molecule in any method that requires the detection and/or quantization of a specific nucleic acid.

A method to inhibit the interaction between a specific interaction between a binding protein and its target nucleic acid comprising introducing an oligourea molecule that specifically competes with the binding protein for the binding site on the target nucleic acid. In a preferred embodiment, the method is a therapeutic method for patients in need of such a treatment. This method is particularly suited as therapeutic method because of the high specificity of the inhibition provided. The therapeutic method is applicable to any disease state in which a nucleic acid-protein interaction affects the disease state. In a preferred embodiment, the patient is human. In a more preferred the patient is infected by the HIV-1 virus, and the oligourea molecule introduced comprises amino acid side chains that correspond to the Tat molecule.

The following Example sets forth the general procedures involved in practicing the present invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. Unless otherwise specified, general cloning procedures, such as those set forth in Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory (1989) (hereinafter "Sambrook et al.") or Ausubel et al. (eds) Current Protocols in Molecular

-10-

Biology, John Wiley & Sons (2000) (hereinafter "Ausubel et al.") are used.

The following example is provided to describe the invention in greater detail. It is intended to  
5 illustrate, not to limit, the invention.

### Example I

We synthesized an oligourea containing the  
10 basic-arginine rich region of Tat by solid phase  
synthesis methods, and tested for TAR RNA binding. This  
tat-derived unnatural biopolymer binds TAR RNA  
specifically with affinities higher than the wild-type  
Tat peptide. Site-specific photocrosslinking experiments  
15 using a photoactive analog (4-thio-uracil) containing TAR  
RNA revealed that the unnatural biopolymer interacts with  
RNA in the major groove. The oligourea-RNA complexes  
were stable to proteolytic digestion. RNA recognition by  
an oligourea provides a new class of RNA-binding  
20 molecules that can be used to control cellular processes  
involving RNA-protein interactions in vivo.

In this report, we synthesized an oligourea  
containing the basic-arginine rich region of Tat by solid  
phase synthesis methods, and tested for TAR RNA binding.  
25 Oligoureas have backbones with hydrogen bonding groups,  
chiral centers, and a significant degree of  
conformational restriction. Introducing additional side  
chains at the backbone NH sites can further modify  
biological and physical properties of these oligomers.  
30 This tat-derived unnatural biopolymer binds specifically  
to TAR RNA with affinities higher than the wild-type Tat  
peptide. These results identify a new class of unnatural  
peptides for structure-specific recognition of RNA.

The promoter of HIV-1, located in the U3 region  
35 of the viral long terminal repeat (LTR), is an inducible

-11-

promoter which can be stimulated by the trans-activator protein, Tat.<sup>3</sup> As in other lentiviruses, Tat protein is essential for trans-activation of viral gene expression.<sup>8</sup> A number of studies showed that Tat-derived peptides  
5 which contain the basic arginine -rich region of Tat are able to form *in vitro* complexes with TAR RNA.<sup>9</sup> We synthesized a tat-derived oligourea containing the basic-arginine rich region of Tat protein by solid phase synthesis methods (Figure 1). Recently, two methods have  
10 been reported for solid phase synthesis of oligourea.<sup>10, 11</sup> To synthesize Tat-derived oligourea on solid support, we used activated *p*-nitrophenyl carbamates and protected amines in the form of azides, which were reduced with SnCl<sub>2</sub>-thiophenol-triethylamine on solid support.<sup>11, 12</sup>  
15 After HPLC purification and characterization by mass spectrometry, the oligourea was tested for TAR RNA binding (Figure 2). The tat-derived oligourea was able to bind TAR RNA and failed to bind a mutant TAR RNA without the bulge residues.

20           Equilibrium dissociation constants of the oligourea-TAR RNA complexes were measured using direct and competition electrophoretic mobility assays.<sup>13</sup> Dissociation constants were calculated from multiple sets of experiments which showed that the oligourea binds TAR  
25 RNA with a  $K_D$  of  $0.11 \pm 0.07 \mu\text{M}$ . To compare the RNA-binding affinities of the oligourea to natural peptide, we synthesized a tat-derived peptide (Tyr47 to Arg57) containing the RNA-binding domain of Tat protein (Figure 1). Dissociation constants of the Tat peptide-RNA  
30 complexes were determined from multiple sets of experiments under the same conditions used for oligourea-TAR RNA complexes. These experiments showed that the Tat peptide (47-57) binds TAR RNA with a  $K_D$  of  $0.78 \pm 0.05 \mu\text{M}$ . A relative dissociation constant ( $K_{REL}$ ) can be determined  
35 by measuring the ratios of wild-type Tat peptide to the

-12-

oligourea dissociation constants ( $K_D$ ) for TAR RNA. Our results demonstrate that the calculated value for  $K_{REL}$  was 7.09, indicating that the urea backbone structure enhanced the TAR binding affinities of the unnatural biopolymer.

Specificity of the oligourea-TAR RNA complex formation was addressed by competition experiments (Figure 2c). Oligourea-RNA complex formation was inhibited by the addition of unlabeled wild-type TAR RNA and not by mutant TAR RNAs. Mutant TAR RNA without a trinucleotide bulge (Figure 2c) or with one base bulge (data not shown) was not able to compete for oligourea binding to wild-type TAR RNA.

Two base-pairs immediately above the pyrimidine bulge are critical for Tat recognition.<sup>9</sup> To determine whether the oligourea recognizes specific base-pairs in the stem region of TAR RNA or only a trinucleotide bulge containing RNA, we synthesized a TAR mutant where the G26-C39 base pair was substituted by a C26-G39 base-pair (Figure 2a). Competition experiments showed that this mutant TAR (G26C) did not inhibit Oligourea binding to TAR RNA (Figure 2c). These results indicate that the tat-derived oligourea can specifically recognize TAR RNA.

To probe the oligourea-RNA interactions and determine the proteolysis stability of oligourea, we synthesized TAR RNA containing 4-thioU at position 23 and performed photocrosslinking experiments as described earlier (Figure 3).<sup>5, 7</sup> Irradiation of the oligourea-RNA complex yields a new band with electrophoretic mobility less than that of the RNA (lane 4). Both the oligourea and UV (360 nm) irradiation are required for the formation of this crosslinked RNA-oligourea complex (see lanes 3 and 4). Since the crosslinked oligourea-RNA complex is stable to alkaline pH (9.5), high temperature (85 °C) and denaturing conditions (8M urea, 2% SDS), we

-13-

conclude that a covalent bond is formed between TAR RNA and the oligourea during the crosslinking reaction.

To test the protease stability of the oligourea-RNA complexes, we subjected the oligourea-RNA crosslink products to very vigorous proteinase K digestion which showed that the complexes were completely stable and there were no signs of oligo urea degradation (lane 5 and 6). Under similar proteinase K treatment, Tat-TAR photocrosslink products resulted in a complete loss of RNA-protein crosslink and a gain in free RNA as observed by band intensities on the gel.<sup>5</sup>

These findings show that a small tat-derived oligourea binds TAR RNA specifically with high affinity and interacts in the major groove (4-thio groups at U23) of TAR RNA. Due to the difference in backbone structure, oligoureas may differ from peptides in hydrogen-bonding properties, lipophilicity, stability, and conformational flexibility. Moreover, oligoureas are resistant to proteinase K degradation. These characteristics of oligoureas may be useful in improving pharmacokinetic properties relative to peptides. RNA recognition by an oligourea provides a new approach for the design of drugs which will modulate RNA-protein interactions. Transfection enhancing agents could be utilized with drugs comprising the oligourea of the invention to ameliorate any problems associated with the transfection or uptake of the oligourea of the invention.

#### REFERENCES

1. (a) Geierstanger, B. H.; Mrksich, M.; Dervan, P. B.; Wemmer, D. E. *Science* 1994, 266, 646-50.  
(b) Gottesfeld, J. M.; Neely, L.; Trauger, J. W.; Baird, B. B.; Dervan, P. B. *Nature* 1997, 387, 202-205.  
(c) White, S.; Szewczyk, J.; Turner, J.; Baird, E.

-14-

- E.; Dervan, P. B. *Nature* 1998, 391, 468-471.
2. Tinoco, I., Jr.; Puglisi, J. D.; Wyatt, J. R. *Nuci. Acids & Mol. Biol.* 1990, 4, 205-226.
3. Jones, K. A.; Peterlin, B. M. *Annu. Rev. Biochem.* 1994, 63, 717-43.
- 5 4. (a) Puglisi, J. D.; Tan, R.; Calnan, B. J.; Frankel, A. D.; Williamson, J. *Science* 1992, 257, 76-80.  
(b) Aboul-ela, F.; Kam, J.; Varani, G. *J Mol. Biol.* 1995, 253, 313-332.
- 10 5. (a) Wang, Z.; Rana, T. M. *J Am. Chem. Soc.* 1995, 117, 5438-5444.  
(b) Wang, z.; Rana, T. M. *Biochemistry* 1996, 35, 6491-6499.  
(c) Wang, Z.; Wang, x.; Rana, T. M. *J Biol. Chem.* 1996, 271, 16995-16998.
- 15 6. Huq, I.; Rana, T. M. *Biochemistry* 1997, 36, 12592-12599.
7. Wang, X.; Huq, I.; Rana, T. M. *J Am. Chem. Soc.* 1997, 119, 6444-6445.
- 20 8. (a) Cullen, B. R. *Microbiol. Rev.* 1992, 56, 375-394.  
(b) Gaynor, R. *AIDS* 1992, 6, 347-363.  
(c) Jeang, K.-T.; Berkhout, B.; Dropulic, B. *J Biol. Chem.* 1993, 268, 24940- 24949.
- 25 9. (a) Calnan, B. J.; Biancalana, S.; Hudson, D.; Frankel, A. D. *Genes Dev.* 1991, 5, 201- 210.  
(b) Weeks, K. M.; Crothers, D. M. *Cell* 1991, 66, 577-588.  
(c) Churcher, M. J.; Lamont, C.; Hamy, F., Dingwall, C.; Green, S. M.; Lowe, A. D.; Butler, P. J. C.; Gait, M. J.; Karn, J. *J Mol. Biol.* 1993, 230, 90-110.
- 30 10. (a) Burgess, K.; Linthicum, D. S.; Shin, H. *Angew. Chem. Int. Ed. Engi.* 1995, 34, 907-909.  
(b) Burgess, K.; Ibarzo, J.; Linthicum, D. S.;

-15-

Russell, D. H.; Shin, H.; Shitangkoon, A.; Totani, R.; Zhang, A. J. *J Am. Chem. Soc.* 1997, 119, 1556-1564.

11. Kim, J. M.; Bi, Y. Z.; Paikoff, S. J.; Schultz, P. G. *Tetrahedron Lett.* 1996, 37, 5305- 5308.
12. Kick, B.; Bllman, J. *J Med. Chem.* 1995, 38, 1427-1430.

-16-

We Claim:

1. A synthesized oligourea comprising all or part of the basic-arginine rich region of Tat.

2. A method of inhibiting the binding of Tat protein to TAR RNA comprising introducing the oligourea of claim 1 into a cellular environment wherein the inhibition is sought to occur.

3. The method of claim 2 wherein the cellular environment is one infected by the HIV-1.

4. The method of claim 3 wherein the oligourea of claim 1 binds to the TAR RNA of HIV-1, thereby limiting the binding of Tat to TAR RNA.

5. A synthesized oligourea comprising all or part of the sequence disclosed in Figure 1A

6. A synthesized oligourea comprising all or part of the structure disclosed in Figure 1B

7. A method of inhibiting the binding of Tat protein to TAR RNA comprising introducing the oligourea of claim 5 into a cellular environment wherein the inhibition is sought to occur.

8. The method of claim 6 wherein the cellular environment is one infected by the HIV-1.

9. The method of claim 8 wherein the oligourea of claim 5 binds to the TAR RNA of HIV-1, thereby limiting the binding of Tat to TAR RNA.



-17-

10. A method of inhibiting the binding of Tat protein to TAR RNA comprising introducing the oligourea of claim 6 into a cellular environment wherein the inhibition is sought to occur.

11. The method of claim 10 wherein the cellular environment is one infected by the HIV-1.

12. The method of claim 11 wherein the oligourea of claim 1 binds to the TAR RNA of HIV-1, thereby limiting the binding of Tat to TAR RNA.

13. A composition that has a high and specific binding affinity for a nucleic acid, comprising oligourea.

14. The composition of claim 13, wherein the oligourea additionally has amino acid side-chains incorporated at the  $R_1$  and  $R_2$  positions of the chemical structure in Figure 1B.

15. The composition of claim 14, wherein the amino acid side chains correspond in sequence to those of a nucleic acid-binding protein.

16. The composition of claim 15, wherein the amino acid side chains correspond to the Tat protein.

17. The composition of claim 16, wherein the amino acid side-chains correspond to residues 48 - 57 of the Tat protein.

18. The composition of claim 17, wherein the amino acid side-chains correspond to SEQ ID NO:1.

-18-

19. The composition of claim 18, wherein the amino acid side-chains correspond to the SEQ ID NO:1 with a L-Tyr amino acid at the carboxyl-terminus.

20. A method of inhibiting a protein-nucleic acid interaction, comprising introducing the composition of claim 13.

21. The method of claim 20, wherein the composition of claim 13 is introduced into a human patient.

22. The method of claim 21, wherein the composition of claim 16 is introduced to a human patient infected by the HIV-1 virus.

23. The method of claim 20, wherein the composition of claim 13 is introduced into an isolated cell.

24. A kit comprising the composition of claim 13 in a container.

25. A kit, comprising the composition of claim 13 in a container and instructions to carry out the method of claim 20.

26. A composition of claim 13, which binds to nucleic acids, which has a disassociation constant ( $K_D$ ) less or equal to 0.70  $\mu$ M.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 July 2000 (27.07.2000)

PCT

(10) International Publication Number  
**WO 00/43332 A3**

- (51) International Patent Classification<sup>7</sup>: A01N 47/28, (74) Agents: REED, Janet, E. et al.; Saul, Ewing, Remick & Saul, L.L.P., Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, PA 19102-2186 (US).  
A61K 31/17, 31/00, C12Q 1/68, 1/58
- (21) International Application Number: PCT/US00/01957
- (22) International Filing Date: 25 January 2000 (25.01.2000) (81) Designated States (national): AU, CA, JP, US.
- (25) Filing Language: English (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (26) Publication Language: English
- (30) Priority Data: 60/117,099 25 January 1999 (25.01.1999) US Published:  
— With international search report.
- (71) Applicant (for all designated States except US): UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY [US/US]; 335 George Street, Suite 3200, New Brunswick, NJ 08903-2688 (US). (88) Date of publication of the international search report: 30 November 2000
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): RANA, Tariq, M. [US/US]; 22 Johanna Court, Piscataway, NJ 08854 (US). For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BIOPOLYMERS COMPRISING HUMAN IMMUNODEFICIENCY VIRUS TAT

(57) Abstract: This invention relates to the use of oligoureia molecules to specifically inhibit protein-nucleic acid interactions. In particular, it provides an oligoureia molecule that competes with the Tat molecule for the TAR RNA of HIV-1. Also provided is a method specifically inhibiting protein-nucleic and interactions, and kits.

WO 00/43332 A3

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07B</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/43332</b> <b>(43) International Publication Date:</b> 27 July 2000 (27.07.00)
<b>(21) International Application Number:</b> PCT/US00/01957 <b>(22) International Filing Date:</b> 25 January 2000 (25.01.00)  <b>(30) Priority Data:</b> 60/117,099 25 January 1999 (25.01.99) US  <b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY [US/US]; 335 George Street, Suite 3200, New Brunswick, NJ 08903-2688 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> RANA, Tariq, M. [US/US]; 22 Johanna Court, Piscataway, NJ 08854 (US). <b>(74) Agents:</b> REED, Janet, E. et al.; Saul, Ewing, Remick & Saul, L.L.P., Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, PA 19102-2186 (US).		<b>(81) Designated States:</b> AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> TAT-DERIVED OLIGOUREA AND ITS METHOD OF PRODUCTION AND USE IN HIGH AFFINITY AND SPECIFIC BINDING OF HIV-1 TAR RNA		
<b>(57) Abstract</b>  This invention relates to the use of oligourea molecules to specifically inhibit protein-nucleic acid interactions. In particular, it provides an oligourea molecule that competes with the Tat molecule for the TAR RNA of HIV-1. Also provided is a method specifically inhibiting protein-nucleic and interactions, and kits.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

<sup>48</sup>Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg<sup>57</sup>

Fig. 1A




Fig. 1B

Fig. 2A




Fig. 2B




Fig. 2C




Fig. 3







Fig. 4



1.

## SEQUENCE LISTING

5 <110> University of Medicine and Dentistry  
of New Jersey  
Rana, T.M.

10 <120> Tat-derived Oligourea and Its Method of  
Production and Use in High Affinity and Specific  
Binding of HIV-1 TAR RNA

<130> RWJ 99-02

15 <150> 60/117,099  
<151> 1999-01-25

<160> 1

20 <170> FastSEQ for Windows Version 3.0

<210> 1

<211> 10

<212> PRT

25 <213> Homo sapiens

<400> 1

Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
1 5 10



266\_255.ST25.txt

SEQUENCE LISTING

<110> RANA, Tariq M.  
TAMILARASU, N.  
HUQ, Ikramul

<120> TAT-DERIVED OLIGOUREA AND ITS METHOD OF PRODUCTION AND  
USE IN HIGH AFFINITY AND SPECIFIC BINDING OF HIV-1 TAR RNA

<130> 266/255

<140> 09/889,982  
<141> 2001-07-25

<150> 60/117,099  
<151> 1999-01-25

<150> PCT/US00/01957  
<151> 2000-01-25

<160> 1

<170> PatentIn version 3.1

<210> 1  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 1

Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
1 5 10